HYALURONIDASE OINTMENT IN TREATMENT OF HYPERTROPHIC SCARS.

We have studied efficiency of hyaluronidase ointment created on the base of microbial hyaluronidase preparation "Bilidase" in treatment of postoperative hypertrophic scars. A total number of 14 patients with postoperative hypertrophic scars on different part of face were enrolled in the study. All patients were treated with hyaluronidase ointment by help of iontophoresis for 10 days -1 procedure per day and than retreated 1 time with the same regimen at 4-week interval. Scar conditions were assessed in terms of pigmentation, vascularity, pliability, height, pain and pruritis in accordance with the Vancouver Scar Scale (VSS). The data of this investigation indicate that treatment of postoperative scars with hyaluronidase ointment significantly improves the function as well as a cosmetic appearance of scar tissues. Each of the investigated parameters was improved significantly after hyaluronidase treatment. Total score after 1 cycle of treatment was 5.14±0.9 vs 10±1.5 before treatment and after 2 cycles of treatment. total score was 0.85±0.9 vs 10±1.5 before treatment (p<0.001). Hyaluronidase ointment could also be recommended for preventing the scar formation in plastic surgery.

[New markers of progression of chronic heart failure in patients with myocardial infarction, type 2 diabetes and obesity].

Currently identified a large number of biomarkers that are closely linked with the development of chronic heart failure, some of which are clusterin and fractalkine. Accordingly, the purpose of our study was - to evaluate the role of clusterin and fractalkine in progression of chronic heart failure in patients with postinfarction cardiosclerosis, type 2 diabetes and obesity. We investigated 71 patients with postinfarction cardiosclerosis, type 2 diabetes and obesity. All patients with postinfarction cardiosclerosis, diabetes and obesity were divided into groups according to the functional class of chronic heart failure (CHF). It was found that an increase the level of fractalkine and reduced clusterin leads due to the development of systolic dysfunction and heart failure progression in patients with postinfarction cardiosclerosis, type 2 diabetes and obesity. Fractalkine and clusterin play an important role in progression of the heart failure in patients with postinfarction cardiosclerosis, type 2 diabetes and obesity, and this gives them the right to be considered indicators of the severity of CHF.